Skip to main content
Premium Trial:

Request an Annual Quote

IP Watch: Hologic, Qiagen, Roche, Others Win US Patents


Gen-Probe (Hologic) has been awarded US Patent No. 8,586,724, "Oligonucleotides for amplifying Chlamydophila pneumonia nucleic acid."

Melissa Cunningham is named as the inventor.

Describes a kit containing two amplification oligonucleotides for amplifying a target sequence from Chlamydophila pneumonia.

GL Sciences has been awarded US Patent No. 8,586,350, "Mechanism of separating and purifying DNA and the like."

Osuman Toujou, Masayoshi Ohira, Kensuke Okusa, Nobuo Seto, and Masahiro Furuno are named as inventors.

Discloses a mechanism for separating and purifying a nucleic acid, particularly fragment DNA, efficiently and with a high reproducibility, without high-concentration salt elution, using a monolith structure formed with glass or silica and having through-pores corresponding to nucleic acid sizes of 35 bp to 100 Kbp.

Response Genetics has been awarded US Patent No. 8,586,311, "Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression."

Kathleen Danenberg is named as the inventor.

Provides methods for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin-embedded tissues, and then determining probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by comparing the amount of TS and/or ERCC1 mRNA in the tumor to a predetermined threshold expression level for those genes.

Roche has been awarded US Patent No. 8,586,299, "Allele-specific amplification."

Stephen Will, Alison Tsan, and Nicolas Newton are named as inventors.

Provides a method of allele-specific amplification, utilizing an oligonucleotide complementary to more than one variant of the target sequence but having a 3'-terminal nucleotide complementary to only one variant, with at least one nucleotide having a base covalently modified at the exocyclic amino group. The allele-specific oligonucleotide is extended by a nucleotide-incorporating biocatalyst predominantly when hybridized to the variant of the target sequence for which it has a complementary 3'-terminal nucleotide.

Washington University has been awarded US Patent No. 8,586,310, "Method for multiplexed nucleic acid patch polymerase chain reaction."

Robi Mitra and Katherine Varley are named as inventors.

Discloses a method for amplifying at least two different nucleic acid sequences using multiplexed nucleic acid patch PCR.

Streck has been awarded US Patent No. 8,586,306, "Preservation of cell-free RNA in blood samples."

Rohan Fernando is named as the inventor.

Discusses a method for preserving and processing cell-free nucleic acids located within a blood sample containing cell-free nucleic acids, to reduce both blood cell lysis and nuclease activity.

Epigenomics has been awarded US Patent No. 8,586,302, "Bisulfite conversion of DNA."

Ina Fuhrmann and Matthias Ballhause are named as inventors.

Describes a method for bisulfite conversion of DNA with improved efficacy in certain time-temperature ranges. Combining the method with denaturating solvents, new reaction conditions, and new purification methods further increases efficacy, and converted DNA can subsequently be analyzed by different methods, particularly facilitating analysis of cytosine methylation.

Stratos Genomics has been awarded US Patent No. 8,586,301, "Multiplexed identification of nucleic acid sequences."

Mark Kokoris and Robert McRuer are named as inventors.

Provides a method for rapid identification of a target nucleic acid sequence associated with, for example, a pathogen. Also provides corresponding devices, products, and kits.

Case Western Reserve University has been awarded US Patent No. 8,586,295, "Method for screening HIV drug sensitivity."

Eric Arts is named as the inventor.

Provides a method for monitoring antiretroviral resistance to determine viral fitness and to forecast possible drug failure. Provides improved personalized HIV/AIDS care to the patient-physician over existing assays at a reduced cost. This set of assays will utilize the same PCR amplicon of the patient HIV genome, which encompasses all of the drug-targeted HIV-1 genes. The advantage of this method over previous is the rapid cloning of this amplicon into an HIV-1 genome vector through yeast recombination/gap repair. The vectors can be directly passed from yeast to a mammalian cell line which has been specifically engineered to produce replication-competent HIV-1 particles to test susceptibility to all antiretrovirals.